Gourdier Benoit 4

What Happened

• Benoit Gourdier, EVP, Bioscience & Medtech at Avantor, was granted equity awards on Feb 19, 2026: 134,364 restricted stock units (RSUs) and a derivative grant of 528,848 stock options (totaling 663,212 shares granted at $0 acquisition price). On Feb 20, 2026, 4,160 shares were disposed/withheld to cover tax withholding obligations (reported value $37,565 at $9.03 per share). These were grants (compensation), not open-market purchases or negative-signal sales.

Key Details

• Transaction dates and amounts:
  • 2026-02-19: Grant (A) — 134,364 RSUs @ $0.00 (acquired)
  • 2026-02-19: Grant (A, derivative) — 528,848 stock options @ $0.00 (acquired)
  • 2026-02-20: Tax withholding (F) — 4,160 shares disposed @ $9.03 = $37,565
• Shares owned after transaction: Not specified in the filing excerpt provided.
• Footnotes:
  • F1: RSUs vest in three equal annual installments beginning Feb 19, 2027.
  • F3: Stock options vest in three equal annual installments beginning Feb 19, 2027.
  • F2: The 4,160-share disposition represents shares withheld by the issuer to satisfy tax withholding.
• Filing timeliness: Form 4 filed Feb 23, 2026 for transactions dated Feb 19–20, 2026 — filed within the required two business days (timely).

Context

• These transactions are compensation grants (RSUs and option awards) that vest over three years; the options are a grant, not an exercised option. The 4,160-share disposition was a routine issuer withholding to cover taxes (code F), not an open-market sale. Grants are common executive compensation and do not by themselves indicate buying or selling sentiment.